Turning Point Therapeutics’ $325 Million Common Stock Offering

Cooley acted as counsel to Turning Point Therapeutics, while Davis Polk advised the joint book-running managers in connection with the offering.

Turning Point Therapeutics, Inc. executed a $325 million SEC-registered common stock offering. The common stock is listed on the Nasdaq Global Select Market under the symbol “TPTX.”

Goldman Sachs & Co. LLC, SVB Leerink LLC, Guggenheim Securities, LLC, Wedbush Securities Inc., and H.C. Wainwright & Co., LLC acted as joint book-running managers in the offering.

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.

Cooley represented Turning Point Therapeutics in the offering.

Davis Polk advised the joint book-running managers with a corporate team included partners Alan F. Denenberg (Picture) and Emily Roberts and associates Donald K. Lang, Daniel Reichert and Dana Lueck-Mammen. The tax team included counsel Ethan R. Goldman and associate M. Jared Sanders. The intellectual property and technology transactions team included counsel Daniel F. Forester and associate Jennifer Leather. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: Alan Denenberg – Davis Polk & Wardwell; Daniel Forester – Davis Polk & Wardwell; Ethan Goldman – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Donald Lang – Davis Polk & Wardwell; Jennifer Leather – Davis Polk & Wardwell; Dana Lueck-Mammen – Davis Polk & Wardwell; Daniel Reichert – Davis Polk & Wardwell; Emily Roberts – Davis Polk & Wardwell; Jared Sanders – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Goldman Sachs & Co.; Guggenheim Securities; H.C. Wainwright & Co.; SVB Leerink LLC; Wedbush Securities;

Author: Ambrogio Visconti